Castle Rock Wealth Management LLC Boosts Stock Holdings in Eli Lilly and Company $LLY

Castle Rock Wealth Management LLC grew its stake in shares of Eli Lilly and Company (NYSE:LLY) by 32.0% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 3,355 shares of the company’s stock after buying an additional 813 shares during the period. Castle Rock Wealth Management LLC’s holdings in Eli Lilly and Company were worth $2,729,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Hengehold Capital Management LLC grew its position in Eli Lilly and Company by 3.1% during the third quarter. Hengehold Capital Management LLC now owns 568 shares of the company’s stock valued at $434,000 after acquiring an additional 17 shares during the period. Greenwood Capital Associates LLC lifted its stake in shares of Eli Lilly and Company by 25.5% in the 3rd quarter. Greenwood Capital Associates LLC now owns 13,169 shares of the company’s stock valued at $10,048,000 after purchasing an additional 2,673 shares in the last quarter. Kempner Capital Management Inc. purchased a new stake in shares of Eli Lilly and Company during the 3rd quarter worth about $1,923,000. Willner & Heller LLC increased its position in Eli Lilly and Company by 5.9% during the 3rd quarter. Willner & Heller LLC now owns 936 shares of the company’s stock worth $714,000 after purchasing an additional 52 shares in the last quarter. Finally, AMI Investment Management Inc. purchased a new position in Eli Lilly and Company in the third quarter valued at approximately $227,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $1,077.26 on Monday. The business’s 50 day moving average is $986.75 and its two-hundred day moving average is $841.60. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,111.99. The firm has a market cap of $1.02 trillion, a price-to-earnings ratio of 52.70, a PEG ratio of 1.09 and a beta of 0.37. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. The business had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The business’s quarterly revenue was up 53.9% compared to the same quarter last year. During the same quarter last year, the company earned $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be paid a $1.73 dividend. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date is Friday, February 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 29.35%.

Analyst Ratings Changes

LLY has been the subject of several research reports. Sanford C. Bernstein reiterated an “outperform” rating on shares of Eli Lilly and Company in a research note on Friday, December 19th. JPMorgan Chase & Co. upped their price target on shares of Eli Lilly and Company from $1,050.00 to $1,150.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 18th. Berenberg Bank increased their price target on Eli Lilly and Company from $830.00 to $950.00 and gave the company a “hold” rating in a report on Tuesday, December 2nd. National Bankshares set a $1,286.00 target price on Eli Lilly and Company in a research report on Monday, December 1st. Finally, Bank of America dropped their target price on Eli Lilly and Company from $1,286.00 to $1,268.00 and set a “buy” rating on the stock in a report on Monday, December 15th. Four analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus target price of $1,155.36.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.